PDF herunterladen
Synthesis 2022; 54(13): 3005-3014
DOI: 10.1055/s-0041-1737911
feature

Synthesis of Phosphoramidate Prodrugs of Phenolic Natural Products and Drugs by Ester Exchange

Jie Yao
a   Institute of Drug Discovery Technology, Ningbo University, Ningbo, Zhejiang, 315211, P. R. of China
b   Qian Xuesen Collaborative Research Center of Astrochemistry and Space Life Sciences, Ningbo University, Ningbo, Zhejiang, 315211, P. R. of China
,
Chengjie Huang
a   Institute of Drug Discovery Technology, Ningbo University, Ningbo, Zhejiang, 315211, P. R. of China
b   Qian Xuesen Collaborative Research Center of Astrochemistry and Space Life Sciences, Ningbo University, Ningbo, Zhejiang, 315211, P. R. of China
,
Fan Wu∗
a   Institute of Drug Discovery Technology, Ningbo University, Ningbo, Zhejiang, 315211, P. R. of China
b   Qian Xuesen Collaborative Research Center of Astrochemistry and Space Life Sciences, Ningbo University, Ningbo, Zhejiang, 315211, P. R. of China
,
Yufen Zhao
a   Institute of Drug Discovery Technology, Ningbo University, Ningbo, Zhejiang, 315211, P. R. of China
b   Qian Xuesen Collaborative Research Center of Astrochemistry and Space Life Sciences, Ningbo University, Ningbo, Zhejiang, 315211, P. R. of China
,
Feng Ni  ∗
a   Institute of Drug Discovery Technology, Ningbo University, Ningbo, Zhejiang, 315211, P. R. of China
b   Qian Xuesen Collaborative Research Center of Astrochemistry and Space Life Sciences, Ningbo University, Ningbo, Zhejiang, 315211, P. R. of China
› InstitutsangabenSupported from the National Natural Science Foundation of China (91856126, 21778042), Scientific Research Grant of Ningbo University (215-432000282), and Ningbo Top Talent Project (215-432094250).
› Weitere Informationen
    Lizenzen und Reprints Alle Artikel dieser Rubrik


Abstract

Drug development based on phenolic natural products as drug candidates against various diseases has gained much attention in recent years. However, most of those molecules lack therapeutic efficacy in clinical trials, usually due to poor bioavailability. Therefore, a prodrug approach was adopted to address the bioavailability problem of phenolic drugs. This paper describes a mild and convenient method for late-stage ProTide-type prodrug synthesis of phenolic pharmaceuticals, which gives various phosphoramidate prodrugs from unprotected phenolic natural products and drugs in high yield. More importantly, this reaction is amenable for the selective phosphorylation of the phenolic hydroxyl group in the presence of otherwise problematic nucleophilic functional groups like amines and alcohols. We also observed that the chemical release rate of the phenol can be substantially tuned by changing the amino acid residue on the phosphoramidate moiety.

Key words

ProTide technology - prodrugs - phenolic drugs - phosphor­yl­ation - drug release - phosphoramidates

Supporting Information

    Supporting information for this article is available online at https://doi.org/10.1055/s-0041-1737911.
  • Supporting Information


Publikationsverlauf

Eingereicht: 11. Januar 2022

Angenommen nach Revision: 14. Februar 2022

Artikel online veröffentlicht:
30. März 2022

© 2022. Thieme. All rights reserved

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Cheynier V, Comte G, Davies KM, Lattanzio V, Martens S. Plant Physiol. Biochem. 2013; 72: 1
    CrossrefPubMed
  • 2 González S, Fernández M, Cuervo A, Lasheras C. J. Hum. Nutr. Diet. 2014; 27: 176
    CrossrefPubMed
  • 3 Archivio M, Filesi C, Varì R, Scazzocchio B, Masella R. Int. J. Mol. Sci. 2010; 11: 1321
    CrossrefPubMed
  • 4 Férriz JM, Vinsová J. Curr. Pharm. Des. 2010; 16: 2033
    CrossrefPubMed

      • Ester prodrugs:
    • 5a Aungst BJ, Myers MJ, Shefter E, Shami EG. Int. J. Pharm. 1987; 38: 199
      Crossref
    • 5b Trapani G, Latrofa A, Franco M, Lopedota A, Maciocco E, Liso G. Int. J. Pharm. 1998; 175: 195
      Crossref

      • Carbonate prodrugs:
    • 5c Orienti I, Zuccari G, Bergamante V, Carosio R, Gotti R, Cilli M. Biomacromolecules 2007; 8: 3258
      CrossrefPubMed

      • Carbamate prodrugs:
    • 5d Garashi Y, Yanagisawa E, Ohshima T, Takeda S, Aburada M, Miyamoto KI. Chem. Pharm. Bull. 2007; 55: 328
      CrossrefPubMed
    • 5e Kim MK, Park K.-s, Yeo W.-s, Choo H, Chong Y. Bioorg. Med. Chem. 2009; 17: 1164
      CrossrefPubMed
    • 6a Leppänen JM, Huuskonen J, Savolainen J, Nevalainen T, Taipale H, Vepsalainen J. Bioorg. Med. Chem. Lett. 2000; 10: 1967
      CrossrefPubMed
    • 6b Baker WR, Cai S, Dimitroff M, Fang L, Huh KK, Ryckman DR. J. Med. Chem. 2004; 47: 4693
      CrossrefPubMed
    • 7a Cahard D, McGuigan C, Balzarini J. Mini-Rev. Med. Chem. 2004; 4: 371
      CrossrefPubMed
    • 7b Mehellou Y, Rattan HS, Balzarini J. J. Med. Chem. 2018; 61: 2211
      CrossrefPubMed
    • 7c Alanazi AS, James E, Mehellou Y. ACS Med. Chem. Lett. 2019; 10: 2
      CrossrefPubMed
    • 7d Serpi M, Pertusati F. Expert Opin. Drug Discovery 2021; 16: 1149
      CrossrefPubMed
    • 8a Slusarczyk M, Lopez MH, Balzarini J, Mason M, Jiang WG, Blagden S, Thompson E, Ghazaly E, McGuigan C. J. Med. Chem. 2014; 57: 1531
      CrossrefPubMed
    • 8b Slusarczyk M, Serpi M, Ghazaly E, Kariuki BM, McGuigan C, Pepper C. J. Med. Chem. 2021; 64: 8179
      CrossrefPubMed
  • 9 McGuigan C, Murziani P, Slusarczyk M, Gonczy B, Vande Voorde J, Liekens S, Balzarini J. J. Med. Chem. 2011; 54: 7247
    CrossrefPubMed
    • 10a McGuigan C, Serpi M, Bibbo R, Roberts H, Hughes C, Caterson B, Gibert AT, Verson CR. A. J. Med. Chem. 2008; 51: 5807
      CrossrefPubMed
    • 10b Serpi M, Bibbo R, Rat S, Roberts H, Hughes C, Caterson B, Alcaraz MJ, Gibert AT, Verson CR. A, McGuigan C. J. Med. Chem. 2012; 55: 4629
      CrossrefPubMed
    • 10c Hamon N, Quintiliani M, Balzarini J, McGuigan C. Bioorg. Med. Chem. Lett. 2013; 23: 2555
      CrossrefPubMed
    • 10d Hamon N, Slusarczyk M, Serpi M, Balzarini J, McGuigan C. Bioorg. Med. Chem. 2015; 23: 829
      CrossrefPubMed
    • 10e James E, Pertusati F, Brancale A, McGuigan C. Bioorg. Med. Chem. Lett. 2017; 27: 1371
      CrossrefPubMed
    • 10f Osgerby L, Lai Y.-C, Thornton PJ, Amalfitano J, Le Duff CS, Jabeen I, Kadri H, Miccoli A, Tucker JH. R, Muqit MM. K, Mehellou Y. J. Med. Chem. 2017; 60: 3518
      CrossrefPubMed
    • 10g Davey MS, Malde R, Mykura RC, Baker AT, Taher TE, Le Duff CS, Willcox BE, Mehellou Y. J. Med. Chem. 2018; 61: 2111
      CrossrefPubMed
  • 11 Wei Y, Qiu G, Lei B, Qin L, Chu H, Lu Y, Zhu G, Gao Q, Huang Q, Qian G, Liao P, Luo X, Zhang X, Zhang C, Li Y, Zheng S, Yu Y, Tang P, Ni J, Yan P, Zhou Y, Li P, Huang X, Gong A, Liu J. J. Med. Chem. 2017; 60: 8580
    CrossrefPubMed
  • 12 Kozak W, Rachon J, Daśko M, Demkowicz S. Asian J. Org. Chem. 2018; 7: 314
    Crossref
  • 13 Procházková E, Navrátil R, Janeba Z, Roithová J, Baszczyňski O. Org. Biomol. Chem. 2019; 17: 315
    CrossrefPubMed